1887

Abstract

The incidence of carbapenem-resistant infection is increasing, which might be associated with high morbidity and mortality among critically ill patients with limited therapeutic options. This study was conducted to evaluate the clinical and microbiological features of carbapenem-resistant bacteraemia. The medical records of 28 adult patients with this bacteraemia admitted to Korea University Guro Hospital, from January 2005 through December 2010, were reviewed. Using the 28 bloodstream isolates, we intended to detect genes encoding carbapenemases, and investigate the inoculum effect on each of the antimicrobial agents rifampicin, imipenem, colistin and tigecycline. With one blood isolate from a patient with pneumonia, rifampicin-inducible resistance was examined using the experimental mouse pneumonia model. Out of 28 carbapenem-resistant bloodstream infections (BIs), the most common primary focus was the central venous catheter (35.7 %) and then the lung (32.1 %). The 30 day overall mortality was 53.6 %; in most cases (80 %) the patients died within 10 days after the onset of the bacteraemia. By univariate analysis, inappropriate antimicrobial therapy (73.3 vs 30.8 %,  = 0.02), mechanical ventilation (53.3 vs 15.4 %,  = 0.04) and a high Pitt bacteraemia score (4.9±1.9 vs 2.2±1.2, <0.01) were statistically significant risk factors for mortality, while only a high Pitt bacteraemia score (odds ratio 2.6; 95 % confidence interval 1.1–6.5) was independently associated with 30 day mortality by multivariate analysis. All 28 isolates had the -like gene with upstream IS, 2 of which additionally had the -like gene and the -like gene. Inoculum effect and rifampicin inducible resistance were not detected. Considering the rapid progression to death in carbapenem-resistant BIs, early empirical antibiotic therapy would be warranted based on the local microbiological data in each hospital.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.029439-0
2011-05-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/5/605.html?itemId=/content/journal/jmm/10.1099/jmm.0.029439-0&mimeType=html&fmt=ahah

References

  1. Aoki N. , Tateda K. , Kikuchi Y. , Kimura S. , Miyazaki C. , Ishii Y. , Tanabe Y. , Gejyo F. , Yamaguchi K. . ( 2009; ). Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa . . J Antimicrob Chemother 63:, 534–542. [CrossRef] [PubMed]
    [Google Scholar]
  2. Bergogne-Bérézin E. , Towner K. J. . ( 1996; ). Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. . Clin Microbiol Rev 9:, 148–165.[PubMed]
    [Google Scholar]
  3. Bernabeu-Wittel M. , García-Curiel A. , Pichardo C. , Pachón-Ibáñez M. E. , Jiménez-Mejías M. E. , Pachón J. . ( 2004; ). Morphological changes induced by imipenem and meropenem at sub-inhibitory concentrations in Acinetobacter baumannii . . Clin Microbiol Infect 10:, 931–934. [CrossRef] [PubMed]
    [Google Scholar]
  4. Corvec S. , Poirel L. , Naas T. , Drugeon H. , Nordmann P. . ( 2007; ). Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii . . Antimicrob Agents Chemother 51:, 1530–1533. [CrossRef] [PubMed]
    [Google Scholar]
  5. Erbay A. , Idil A. , Gözel M. G. , Mumcuoğlu I. , Balaban N. . ( 2009; ). Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. . Int J Antimicrob Agents 34:, 575–579. [CrossRef] [PubMed]
    [Google Scholar]
  6. Giamarellos-Bourboulis E. J. , Xirouchaki E. , Giamarellou H. . ( 2001; ). Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii . . Diagn Microbiol Infect Dis 40:, 117–120. [CrossRef] [PubMed]
    [Google Scholar]
  7. Glew R. H. , Moellering R. C. Jr , Kunz L. J. . ( 1977; ). Infections with Acinetobacter calcoaceticus (Herellea vaginicola): clinical and laboratory studies. . Medicine (Baltimore) 56:, 79–97.[PubMed] [CrossRef]
    [Google Scholar]
  8. Héritier C. , Poirel L. , Nordmann P. . ( 2006; ). Cephalosporinase over-expression resulting from insertion of ISAba1 in Acinetobacter baumannii . . Clin Microbiol Infect 12:, 123–130. [CrossRef] [PubMed]
    [Google Scholar]
  9. Kwon K. T. , Oh W. S. , Song J. H. , Chang H. H. , Jung S. I. , Kim S. W. , Ryu S. Y. , Heo S. T. , Jung D. S. et al. ( 2007; ). Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia . . J Antimicrob Chemother 59:, 525–530. [CrossRef] [PubMed]
    [Google Scholar]
  10. Lee K. , Chong Y. , Shin H. B. , Kim Y. A. , Yong D. , Yum J. H. . ( 2001; ). Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species. . Clin Microbiol Infect 7:, 88–91. [CrossRef] [PubMed]
    [Google Scholar]
  11. Lee S. O. , Kim E. S. , Kim H. Y. , Park E. S. , Jin H. Y. , Ki H. K. , Choi H. J. , Jeong S. Y. , Kim S. R. et al. ( 2008; ). [Korean nosocomial infections surveillance system, intensive care unit module report: data summary from July 2007 through June 2008]. . Korean J Nosocomial Infect Control 13:, 69–82 (in Korean).
    [Google Scholar]
  12. Li J. , Nation R. L. , Owen R. J. , Wong S. , Spelman D. , Franklin C. . ( 2007; ). Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. . Clin Infect Dis 45:, 594–598. [CrossRef] [PubMed]
    [Google Scholar]
  13. Maragakis L. L. , Perl T. M. . ( 2008; ). Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. . Clin Infect Dis 46:, 1254–1263. [CrossRef] [PubMed]
    [Google Scholar]
  14. Metan G. , Sariguzel F. , Sumerkan B. . ( 2009; ). Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia . . Eur J Intern Med 20:, 540–544. [CrossRef] [PubMed]
    [Google Scholar]
  15. Munoz-Price L. S. , Weinstein R. A. . ( 2008; ). Acinetobacter infection. . N Engl J Med 358:, 1271–1281. [CrossRef] [PubMed]
    [Google Scholar]
  16. Pachón-Ibáñez M. E. , Fernández-Cuenca F. , Docobo-Pérez F. , Pachón J. , Pascual A. . ( 2006; ). Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. . J Antimicrob Chemother 58:, 689–692. [CrossRef] [PubMed]
    [Google Scholar]
  17. Pankey G. A. . ( 2005; ). Tigecycline. . J Antimicrob Chemother 56:, 470–480. [CrossRef] [PubMed]
    [Google Scholar]
  18. Peleg A. Y. , Seifert H. , Paterson D. L. . ( 2008; ). Acinetobacter baumannii: emergence of a successful pathogen. . Clin Microbiol Rev 21:, 538–582. [CrossRef] [PubMed]
    [Google Scholar]
  19. Poirel L. , Nordmann P. . ( 2006; ). Genetic structures at the origin of acquisition and expression of the carbapenem-hydrolyzing oxacillinase gene bla OXA-58 in Acinetobacter baumannii . . Antimicrob Agents Chemother 50:, 1442–1448. [CrossRef] [PubMed]
    [Google Scholar]
  20. Poutanen S. M. , Louie M. , Simor A. E. . ( 1997; ). Risk factors, clinical features and outcome of Acinetobacter bacteremia in adults. . Eur J Clin Microbiol Infect Dis 16:, 737–740. [CrossRef] [PubMed]
    [Google Scholar]
  21. Saballs M. , Pujol M. , Tubau F. , Peña C. , Montero A. , Domínguez M. A. , Gudiol F. , Ariza J. . ( 2006; ). Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. . J Antimicrob Chemother 58:, 697–700. [CrossRef] [PubMed]
    [Google Scholar]
  22. Seifert H. , Strate A. , Pulverer G. . ( 1995; ). Nosocomial bacteremia due to Acinetobacter baumannii: clinical features, epidemiology, and predictors of mortality. . Medicine (Baltimore) 74:, 340–349. [CrossRef] [PubMed]
    [Google Scholar]
  23. Song J. Y. , Kee S. Y. , Hwang I. S. , Seo Y. B. , Jeong H. W. , Kim W. J. , Cheong H. J. . ( 2007; ). In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii . . J Antimicrob Chemother 60:, 317–322. [CrossRef] [PubMed]
    [Google Scholar]
  24. Song J. Y. , Lee J. , Heo J. Y. , Noh J. Y. , Kim W. J. , Cheong H. J. , Hwang I. S. . ( 2008; ). Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii . . Int J Antimicrob Agents 32:, 281–284. [CrossRef] [PubMed]
    [Google Scholar]
  25. Song J. Y. , Cheong H. J. , Lee J. , Sung A. K. , Kim W. J. . ( 2009; ). Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. . Int J Antimicrob Agents 33:, 33–39. [CrossRef] [PubMed]
    [Google Scholar]
  26. Turton J. F. , Ward M. E. , Woodford N. , Kaufmann M. E. , Pike R. , Livermore D. M. , Pitt T. L. . ( 2006; ). The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii . . FEMS Microbiol Lett 258:, 72–77. [CrossRef] [PubMed]
    [Google Scholar]
  27. Wareham D. W. , Bean D. C. , Khanna P. , Hennessy E. M. , Krahe D. , Ely A. , Millar M. . ( 2008; ). Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. . Eur J Clin Microbiol Infect Dis 27:, 607–612. [CrossRef] [PubMed]
    [Google Scholar]
  28. CLSI (2006). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, approved standard, 7th edn, M7–A7. Wayne, PA: Clinical and Laboratory Standards Institute.
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.029439-0
Loading
/content/journal/jmm/10.1099/jmm.0.029439-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error